Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 12/20 | 0.59 |
| ▸ | CTNNB1 | P35222 | 12/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | UBE2M | P61081 | 1/20 | 0.44 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23124979 | 1.00 | BCL9 (0.59) | BCL9CTNNB1OPRM1UBE2MDCUN1D1 | |
| SCHEMBL23124502 | 1.00 | BCL9 (0.59) | BCL9CTNNB1OPRM1UBE2MDCUN1D1 | |
| SCHEMBL23124749 | 0.87 | BCL9 (0.58) | BCL9CTNNB1PKMHTTSMN1; SMN2 | |
| SCHEMBL23124751 | 0.87 | BCL9 (0.58) | BCL9CTNNB1PKMHTTSMN1; SMN2 | |
| SCHEMBL30093566 | 0.86 | BCL9 (0.58) | BCL9CTNNB1HTTALDH1A1 | |
| SCHEMBL30093616 | 0.86 | BCL9 (0.58) | BCL9CTNNB1HTTALDH1A1 | |
| SCHEMBL23124873 | 0.86 | BCL9 (0.58) | BCL9CTNNB1HTTALDH1A1 | |
| SCHEMBL23124721 | 0.86 | BCL9 (0.58) | BCL9CTNNB1PKMHTTSMN1; SMN2 | |
| SCHEMBL23124575 | 0.86 | BCL9 (0.58) | BCL9CTNNB1PKMHTTSMN1; SMN2 | |
| SCHEMBL23124723 | 0.86 | BCL9 (0.58) | BCL9CTNNB1PKMHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2021055936-A1 | SMALL-MOLECULE INHIBITORS FOR THE Β-CATENIN/B-CELL LYMPHOMA 9 PROTEIN−PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | BCL9 1/4885CTNNB1 9/4885OPRM1 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.